Attrv122i amyloidosis is a genetic condition that causes abnormal protein to build up in nerves and the heart. Many people with ATTRv122I amyloidosis develop numbness, tingling, pain, or weakness in the legs and feet, and some have shortness of breath, swelling, or fatigue from heart involvement. It usually progresses over years and most often affects adults, with higher frequency in people of West African ancestry. Treatment focuses on slowing protein buildup with targeted medicines, easing nerve pain, and supporting heart function, and some may be candidates for gene‑silencing therapy. The outlook varies by age at onset and organ involvement, but earlier diagnosis and modern treatments have improved survival.
Overview
Attrv122i amyloidosisSymptoms
Early symptoms of ATTRv122i amyloidosis often include breathlessness on exertion, leg swelling, fatigue, and palpitations. Some develop chest discomfort, dizziness or fainting, carpal tunnel–like hand numbness, or bowel and weight changes.
Outlook and prognosis
Most people with ATTRv122I amyloidosis develop slowly worsening heart stiffness and fatigue over years, with outlook shaped by age at diagnosis and heart involvement. Early recognition, salt management, diuretics, rhythm care, and TTR-targeted drugs can slow progression. Regular follow-up guides timely adjustments.
Causes and risk factors
ATTR V122I amyloidosis is caused by a TTR gene change (Val122Ile), usually inherited in an autosomal-dominant way. Risk rises with age and is higher among people of West African ancestry. Male sex, heart strain, and other illnesses may hasten symptoms.
Genetic influences
Genetics are central to ATTRV122I amyloidosis; a specific TTR gene variant (Val122Ile) causes the disease. It’s inherited in an autosomal‑dominant pattern, so one altered copy can be enough. Genetic testing and family screening help with early diagnosis and management.
Diagnosis
Doctors suspect Attrv122i amyloidosis from clinical features like thickened heart walls or nerve symptoms, then confirm with tests. Genetic diagnosis of Attrv122i amyloidosis uses a TTR gene test, plus imaging or biopsy to show amyloid and rule out AL.
Treatment and drugs
Treatment for ATTRv122I amyloidosis focuses on slowing nerve and heart damage, easing symptoms, and supporting daily function. Options may include TTR stabilizers, gene-silencing therapies, diuretics for fluid, rhythm control, and careful pain and neuropathy management. Multidisciplinary, heart–neurology care is key.
Symptoms
Attrv122i amyloidosis most often affects the heart, leading to heart failure–type features that can limit daily activities. People may notice early features of Attrv122i amyloidosis like shortness of breath, ankle swelling, or a fast or irregular heartbeat. Hand numbness from carpal tunnel can also appear, sometimes years before heart issues. Features vary from person to person and can change over time.
Breathlessness may show up during walks, climbing stairs, or when lying flat. In Attrv122i amyloidosis, the heart can become stiff, making it harder to move blood efficiently. Waking up at night feeling short of breath can also happen.
Feet, ankles, or lower legs can puff up over the day, and socks may leave deeper marks. This swelling reflects fluid buildup when the heart doesn’t relax and fill normally. Shoes may feel tighter by evening.
Ongoing tiredness and reduced stamina can make chores or errands harder. What once felt effortless can start to require more energy or focus. Many people cut back activity without realizing why.
A fast, slow, or uneven pulse can feel like fluttering or skipped beats. In Attrv122i amyloidosis, an irregular rhythm called atrial fibrillation can occur and sometimes raises stroke risk. Palpitations can come and go or persist.
How people usually first notice Attrv122i amyloidosis?
Many people first notice ATTRv V122I amyloidosis as slowly building heart-related changes in mid to later adulthood, such as unexplained shortness of breath on exertion, swelling in the legs or ankles, or fatigue that feels out of proportion to activity. It’s often picked up when a doctor finds thickened heart walls on an echocardiogram with preserved pumping strength, or when symptoms don’t improve as expected for “typical” heart failure, especially in people of West African ancestry, where this variant is more common. For some, the first signs of ATTRv V122I amyloidosis also include carpal tunnel symptoms or numbness and tingling in the hands before the cardiac issues become clear.
Types of Attrv122i amyloidosis
Attrv122i amyloidosis is a genetic condition with recognized clinical variants based on the specific change in the transthyretin (TTR) gene and how the disease shows up in the heart, nerves, or both. Some variants are defined by the gene change itself, while others describe the main organ system involved. People may notice different sets of symptoms depending on their situation. When discussing types of ATTRv amyloidosis, doctors usually group them by the variant gene change and the dominant organ features, which helps explain why symptoms can differ from one person to another.
Val122Ile cardiac-predominant
This variant most often affects the heart muscle, leading to thickened, stiff walls and heart failure symptoms like breathlessness and leg swelling. Many develop rhythm problems and reduced exercise tolerance over time.
Val30Met early-onset
This classic neuropathic variant typically starts with nerve symptoms such as numbness, tingling, and burning pain in the feet and hands, sometimes with digestive changes and weight loss. Heart involvement can appear later but is often milder early on.
Val30Met late-onset
A later-life presentation of the same Val30Met change can include mixed nerve and heart features, often with walking imbalance and autonomic symptoms like lightheadedness on standing. Cardiac thickening and conduction issues are more common than in early-onset cases.
Thr60Ala mixed phenotype
People often have both nerve and heart involvement, with numbness, weakness, and carpal tunnel features alongside heart stiffness. Shortness of breath, swelling, and fatigue can worsen as cardiac disease progresses.
Ile68Leu cardiac-focused
This variant is frequently linked to heart-dominant disease with thickened walls and reduced filling of the heart. Symptoms may include fatigue, shortness of breath with activity, and fluid buildup in the legs or abdomen.
Phe64Leu neuropathic
Nerve symptoms are prominent, including painful neuropathy and temperature or pain-sensing changes in the feet and hands. Some develop digestive issues or unintentional weight loss as the autonomic nerves are affected.
Glu89Gln mixed involvement
Both peripheral nerves and the heart can be affected, with gradual loss of sensation and strength along with signs of cardiomyopathy. Early symptoms of ATTRv amyloidosis in this variant may include carpal tunnel syndrome or gastrointestinal changes.
Non-V122I cardiac ATTRv
Several other TTR gene changes can cause mainly heart disease similar to Val122Ile but with different ages of onset. Features include heart wall thickening, shortness of breath, and rhythm disturbances.
Non-V30M neuropathic ATTRv
Multiple TTR variants primarily cause nerve-predominant disease resembling Val30Met neuropathy. People may experience painful small-fiber neuropathy, balance problems, and autonomic symptoms such as constipation or diarrhea.
Wild-type ATTR (note)
Wild-type ATTR is not a genetic variant and therefore is not a type of ATTRv amyloidosis. It is an acquired form that mainly affects the heart and can include carpal tunnel syndrome.
What genetics can tell you about symptoms
In ATTR V122I amyloidosis, a single-letter change in the TTR gene makes the transthyretin protein unstable, so it misfolds and builds up in the heart. Many—especially people of West African ancestry—develop worsening shortness of breath, leg swelling, fatigue, and irregular heartbeats.
Causes and risk factors
Attrv122i amyloidosis starts with a change in the transthyretin (TTR) gene called V122I.
Having a gene change doesn’t mean you’ll definitely develop the condition.
Risk is higher with older age, in men, and in people with African or African American ancestry.
It is usually inherited from a parent, though a new change can rarely appear for the first time.
Lifestyle and health factors do not cause it, but overall heart health can shape when early symptoms of Attrv122i amyloidosis appear and how severe they become.
Environmental and biological risk factors
Attrv122i amyloidosis often shows up later in adulthood and most commonly involves the heart. Beyond who carries the underlying change, body-based and environmental factors can influence whether and when symptoms appear. That said, biology and environment work hand in hand. Below are key factors tied to a higher likelihood of clinical signs emerging.
As the body ages, natural protein-clearance systems slow and misfolded proteins can accumulate more easily. Many people with Attrv122i amyloidosis first notice symptoms after age 60.
Men are more likely to develop heart involvement from this condition and often at an earlier age than women. Differences in hormones and heart structure may contribute.
Long-standing high blood pressure or a tight aortic valve can increase stress on the heart muscle. Extra strain may make stiffness from amyloid noticeable sooner in Attrv122i amyloidosis.
Genetic risk factors
A single inherited change in the TTR gene is the key driver of ATTRv122I amyloidosis. Inheritance is autosomal dominant, meaning one altered copy can raise the chance of heart amyloid. Carrying a genetic change doesn’t guarantee the condition will appear. Genetic testing for ATTRv122I amyloidosis can help identify which relatives carry the variant and guide follow-up.
TTR V122I variant: The V122I change in the TTR gene makes the transthyretin protein less stable and prone to form amyloid in the heart. This is the primary genetic cause of ATTRv122I amyloidosis.
Autosomal dominant inheritance: One altered copy of TTR is enough to confer risk. Each child of a carrier has a 50% (1 in 2) chance to inherit the variant.
West African ancestry: The V122I variant is most common in people with West African ancestry, including many African American and Afro-Caribbean families. About 3–4% carry the variant, which raises the chance of developing ATTRv122I amyloidosis later in life.
Family history: Having a parent or sibling with the V122I variant increases your likelihood of carrying it. Relatives can consider carrier testing to clarify their personal risk.
Variable penetrance: Not everyone who carries V122I will develop disease. For those who do, problems often begin in later adulthood, commonly after age 60.
Sex differences: Men who carry V122I are more likely than women to develop cardiomyopathy and may present earlier. Women can still be affected, so periodic heart checks remain important.
Two variant copies: Inheriting two V122I copies is rare but can increase the chance of earlier onset or more severe disease. This is more likely if both parents carry the variant.
Other TTR variants: Changes in other positions of TTR can also cause hereditary ATTR and may shift organ involvement patterns. If different variants run in a family, specialized counseling can help explain the combined risk.
Lifestyle risk factors
Attrv122i amyloidosis is inherited; lifestyle habits do not cause it, but they can influence symptoms, flares, and complication risks. The focus below is how lifestyle affects Attrv122i amyloidosis in day-to-day life. Understanding the lifestyle risk factors for Attrv122i amyloidosis can help you tailor choices that ease heart and nerve strain.
High-salt meals promote fluid retention and can worsen leg swelling and shortness of breath in amyloid cardiomyopathy. Prioritizing low-sodium eating reduces congestion and may improve exercise tolerance.
Excess fluids can aggravate heart failure symptoms and edema. Following a clinician-set daily fluid goal helps balance dehydration risks with congestion control.
Regular low-to-moderate aerobic activity can improve stamina and reduce deconditioning in ATTR cardiomyopathy. Avoiding heavy lifting and extreme exertion lowers risks of arrhythmia, dizziness, or syncope.
Heavy drinking is directly cardiotoxic and can worsen heart stiffness and pumping function. Alcohol also aggravates peripheral neuropathy, increasing pain and numbness.
Risk prevention
Attrv122i amyloidosis is inherited, so the gene itself can’t be changed, but you can lower complications and catch heart changes early. Prevention is about lowering risk, not eliminating it completely. Family testing and regular heart checks can find issues before they cause symptoms. Day-to-day heart-healthy habits also help protect your heart and stamina over time.
Talk with a genetics professional about testing and what results mean for you and relatives. When one person tests positive, offering testing to close family can help with early detection and planning.
Schedule periodic heart ultrasounds, heart rhythm tests, and blood tests to look for early strain. Finding changes early supports timely treatment if ATTR cardiomyopathy begins.
Learn the early symptoms of ATTRv122i amyloidosis, such as breathlessness with stairs, swelling in the legs, or a racing or irregular heartbeat. Noticing patterns sooner can prompt earlier care and reduce complications.
If you have the variant, encourage adult relatives to consider testing. Knowing who carries the variant focuses monitoring on those most likely to benefit.
Transmission
ATTRv122I amyloidosis is not contagious; you can’t catch it or pass it through everyday contact, saliva, sex, or blood. It results from a change in the TTR gene and follows an autosomal dominant pattern—if a parent carries the variant, each child has a 1 in 2 (50%) chance of inheriting it. This is the genetic transmission of ATTRv122I amyloidosis, and most people with it inherited the variant from a parent; brand‑new (de novo) changes causing this specific variant are uncommon. Inherited risk doesn’t always equal illness, though—some who inherit the variant never develop symptoms, and many develop problems later in adulthood—so families often consider genetic counseling and testing to understand how ATTRv122I amyloidosis is inherited.
When to test your genes
Test if you have a family history of ATTRv (V122I) amyloidosis, unexplained heart failure—especially thickened heart walls—or neuropathy in midlife or later, or if you’re of West African ancestry where this variant is more common. Consider testing before symptoms to guide screening and treatment timing. Discuss results with a genetic counselor to plan care.
Diagnosis
Living with breathlessness on the stairs, ankle swelling by evening, or fatigue that doesn’t match your activity can prompt questions about your heart. In ATTRv V122I amyloidosis, doctors look for a pattern of heart changes and then confirm it with specific tests, including genetic testing. Early and accurate diagnosis can help you plan ahead with confidence. The genetic diagnosis of ATTRv V122I amyloidosis typically combines clinical clues, heart imaging, lab tests to rule out other causes, and confirmation of a transthyretin gene variant.
Providers look for heart failure symptoms such as shortness of breath, swelling in the legs, and reduced exercise tolerance. They also note features doctors see, like thickened heart walls on imaging or low blood pressure on standing.
A detailed family and health history can help identify patterns of heart problems, heart failure, or sudden cardiac deaths, especially in relatives of African or Afro-Caribbean ancestry. This background can raise suspicion for ATTRv V122I amyloidosis.
Doctors usually begin with tests for abnormal light chains to rule out a different type called AL amyloidosis. These include serum free light chains and protein studies in blood and urine.
Blood tests such as NT‑proBNP and troponin can signal stress or injury in the heart. While not specific, they help gauge severity and track changes over time.
Stages of Attrv122i amyloidosis
In ATTRv122I amyloidosis, staging focuses on how much the heart is affected over time. Early and accurate diagnosis helps you plan ahead with confidence. Doctors commonly use a three‑stage system based on a heart‑strain blood test (NT‑proBNP) and kidney filtering (eGFR), because these give a clear picture of overall stress on the body.
Stage I early
Symptoms may be mild or occasional, like shortness of breath with hills or carrying groceries and mild leg swelling by day’s end. Blood tests usually show NT‑proBNP at or below 3,000 ng/L and eGFR at or above 45 mL/min/1.73 m².
Stage II moderate
Daily activities can start to feel limited, with more frequent breathlessness, fatigue, or ankle swelling. At this stage, either NT‑proBNP is above 3,000 ng/L or eGFR is below 45 mL/min/1.73 m².
Stage III advanced
Symptoms are often present at rest or with very light activity, and fluid buildup in the legs or abdomen may be more noticeable. Both NT‑proBNP is above 3,000 ng/L and eGFR is below 45 mL/min/1.73 m²; early symptoms of ATTRv122I amyloidosis may have progressed to persistent shortness of breath and marked tiredness.
Outlook and prognosis
Looking ahead can feel daunting, but most people with ATTRv V122I amyloidosis want to know how life may change over time. The outlook is not the same for everyone, but symptoms usually start in mid- to later adulthood and tend to progress over years. Many people first notice breathlessness on stairs, ankle swelling, fatigue, or a “heavy” heartbeat; others may have carpal tunnel or lightheadedness. Prognosis refers to how a condition tends to change or stabilize over time, and for ATTRv V122I amyloidosis this is closely tied to heart involvement.
Without treatment, ATTRv V122I amyloidosis can lead to heart failure over time, which raises the risk of hospitalization and shorter survival. With the right support, the future can be brighter than it used to be because newer disease‑modifying drugs can slow protein buildup and may improve symptoms. Early symptoms of ATTRv V122I amyloidosis can be subtle, so recognizing them and starting therapy sooner is linked with better function and, in some studies, longer life. In medical terms, the long‑term outlook is often shaped by both genetics and lifestyle, including blood pressure control, salt intake, and staying active within safe limits.
Mortality depends on how advanced the heart disease is at diagnosis, other health conditions, and how quickly treatment begins; some people live many years with careful management, while others with late‑stage disease face a shorter timeline. Supportive care—managing fluid balance, avoiding certain heart drugs that may worsen symptoms, and treating rhythm problems—also affects quality of life day to day. Knowing what to expect can ease some of the worry, and practical planning with your care team can help you stay active and independent as long as possible. Talk with your doctor about what your personal outlook might look like, including which treatments fit your goals and when to start them.
Long-term effects
For many, ATTRv122I amyloidosis gradually stiffens the heart, so everyday activities feel harder over time. You might notice breathlessness on stairs that used to feel easy, or swelling in your ankles by evening. Long-term effects vary widely, and they tend to build slowly over years. Here’s what doctors and research know about how the condition can affect life down the road.
Shortness of breath, leg swelling, and fatigue can increase as the heart muscle stiffens in ATTRv122I amyloidosis. Many people find walking distances and climbing stairs become harder over time.
Irregular beats like atrial fibrillation and conduction blocks can develop. This can cause palpitations, dizzy spells, or the need for a pacemaker.
Stamina often declines, narrowing the range of daily activities. Over time, daily routines may need shorter tasks with more breaks.
Congestion in the lungs and swelling in the legs or abdomen can recur. This often leads to hospital stays for worsening heart failure in ATTRv122I amyloidosis.
How is it to live with Attrv122i amyloidosis?
Living with ATTRv V122I amyloidosis often means watching stamina shrink in slow, uneven steps—climbing stairs takes more effort, legs may swell, and walks that once felt easy can leave you breathless. Many notice fatigue, ankle swelling, and reduced exercise tolerance from heart stiffness, while some also feel numbness or tingling in the feet; day-to-day plans may start revolving around pacing, rest breaks, and regular cardiology visits. For family, the ripple is real: loved ones may help with appointments and household tasks, and because this is an inherited variant common in people of West African ancestry, relatives may face decisions about genetic testing and screening. With treatment options, symptom-focused care, and thoughtful planning, many people preserve independence and keep meaningful routines, even if the tempo of life changes.
Treatment and drugs
Treatment for ATTRv V122I amyloidosis focuses on slowing the buildup of transthyretin (TTR) amyloid and easing symptoms that affect the heart and nerves. Doctors may use TTR stabilizers (such as tafamidis) to help keep the TTR protein from misfolding, and gene-silencing medicines (like patisiran, vutrisiran, or inotersen) to reduce the liver’s production of TTR; these aim to slow disease progression and can improve quality of life. For heart-related issues, care often includes diuretics to manage fluid, careful blood pressure control, rhythm monitoring, and sometimes devices for abnormal heart rhythms; physical therapy, pain control, and nutrition support help with nerve symptoms. Treatment plans often combine several approaches. Ask your doctor about the best starting point for you, including eligibility for specific drugs and clinical trials.
Non-drug treatment
Day-to-day life with Attrv122i amyloidosis often revolves around managing shortness of breath, swelling, and low energy while keeping your heart as steady as possible. Alongside medicines, non-drug therapies can support your heart, protect your independence, and make symptoms more predictable. Care plans are personalized, and what helps most can change over time as the condition progresses. Many find that small, steady adjustments add up to better stamina and fewer flare-ups.
Structured programs, like supervised cardiac rehabilitation, can help build stamina safely. A team guides pacing, breathing, and recovery so activity feels doable.
Cutting back on salt can reduce ankle swelling and breathlessness. Reading labels and cooking at home make it easier to keep sodium low.
Tracking daily weight helps catch fluid buildup early. Your care team can set a safe fluid target and adjust it if swelling or shortness of breath worsens.
Graduated compression socks and leg elevation can limit ankle and leg swelling. This may ease heaviness and make walking more comfortable.
Your genes may have an impact on how drugs work for you
Medicines for ATTRv V122I amyloidosis can work differently based on gene variants that affect drug processing, target proteins, and side‑effect risk. Pharmacogenetic testing may guide dosing and drug choice, but clinical factors like heart and kidney function still matter.
Pharmacological treatments
Medicines for ATTRv122i amyloidosis aim to slow the disease, protect the heart, and ease day‑to‑day symptoms like breathlessness and swelling. First-line medications are those doctors usually try first, based on how well they work and their safety in large studies. For ATTRv122i amyloidosis (a hereditary transthyretin condition that mainly affects the heart), starting disease‑modifying therapy early may preserve function, even if early symptoms of ATTRv122i amyloidosis are subtle. Your exact plan depends on heart rhythm, kidney function, other conditions, and what’s available in your region.
A transthyretin stabilizer that slows amyloid buildup in the heart. It reduces cardiovascular hospitalizations and the risk of death in ATTR cardiomyopathy.
A newer transthyretin stabilizer for ATTR cardiomyopathy. It has shown improvements in heart-related outcomes and quality of life, and may be used when tafamidis is not suitable.
An RNA-silencing injection that lowers transthyretin production from the liver. Given every 3 months under the skin, it can improve walking capacity and quality of life in ATTR amyloidosis and is authorized for cardiomyopathy in some regions.
An RNA-silencing infusion approved for hereditary ATTR with nerve involvement. It is not broadly approved for cardiomyopathy in the United States, but specialists may consider it in select cases depending on regional guidance.
Genetic influences
Attrv122i amyloidosis is driven by an inherited change in the TTR gene that makes the transthyretin protein unstable and prone to forming deposits, most often in the heart. This specific change, often called V122I, is passed in an autosomal dominant way, so each child of someone who carries it has a 50% chance to inherit it, though the age it appears and how strongly it affects someone can vary. Family history is one of the strongest clues to a genetic influence. The variant is relatively common in people with West African ancestry and typically leads to symptoms later in adulthood, which means a pattern across generations may be overlooked or mistaken for age‑related heart disease. A DNA test using blood or saliva can identify the TTR variant, and genetic counseling can help you understand what the result means for you and your relatives. Knowing your risk can prompt checkups for early symptoms of Attrv122i amyloidosis, such as gradually worsening shortness of breath, ankle swelling, or fatigue tied to heart changes.
Is Attrv122i amyloidosis genetic?
Genetics are central to ATTRV122I amyloidosis; a specific TTR gene variant (Val122Ile) causes the disease. It’s inherited in an autosomal‑dominant pattern, so one altered copy can be enough. Genetic testing and family screening help with early diagnosis and management.
Pharmacogenetics—how genetics influence drug effects
Treatment choices are shaped by the specific change in the TTR gene that causes the disease. In this condition, the V122I variant tends to affect the heart, so doctors often consider medicines that stabilize the TTR protein (such as tafamidis) or lower its production (for example, patisiran or vutrisiran). Evidence so far suggests these therapies can help across different TTR variants, and dosing is not tailored to V122I specifically. Alongside your medical history and heart imaging, genetic testing can help confirm the exact TTR change, guide family screening, and support earlier use of disease-modifying therapy. Broader pharmacogenetic testing may matter for some of the supportive heart medicines you might also take (for example, blood thinners or pain relievers), because common gene differences can change how quickly your body processes them. For families, knowing the variant allows relatives to seek genetic counseling and, if appropriate, start monitoring sooner; genetic testing for Attrv122i amyloidosis can also open the door to clinical trials.
Interactions with other conditions
Many people with Attrv122i amyloidosis also live with high blood pressure or coronary artery disease, which can blur the picture when breathlessness, ankle swelling, or fatigue get worse. Doctors call it a “comorbidity” when two conditions occur together. Hypertension and long-standing diabetes can stiffen the heart on their own, and when amyloidosis is present, the combined effect can make heart failure symptoms flare with smaller triggers, like a salty meal or a mild infection. Irregular heart rhythm (atrial fibrillation) is common, and the fluttering or pauses can unmask early symptoms of ATTRv V122I amyloidosis; blood thinners are often needed, but the choice may be shaped by kidney health or other illnesses.
Calcium build-up on the aortic valve (aortic stenosis) can occur alongside transthyretin amyloid in older adults; fixing the valve, sometimes with a catheter procedure, may help, but amyloid-related heart stiffness and low blood pressure can still limit stamina. Because some heart medicines are harder to tolerate in amyloidosis—such as certain calcium channel blockers or higher-dose beta blockers—treatment plans for hypertension, coronary disease, or heart failure are often adjusted to prevent dizziness and fainting. If blood tests show a monoclonal protein, doctors will also check for AL amyloidosis, because having ATTRv V122I amyloidosis does not rule out a second type of amyloid, and each requires very different treatment.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns that seemed to run through generations—an older relative who lost feeling in the feet, another with unexplained weight loss and weakness, someone else whose heart seemed to tire too soon. Looking back, these stories align with what we now recognize as ATTRv V122I amyloidosis, a hereditary form of transthyretin amyloidosis that tends to affect the heart and nerves in adulthood.
First described in the medical literature as a variant seen predominantly in people of West African ancestry, the V122I change in the transthyretin gene was initially linked to heart muscle stiffness and heart failure symptoms that appeared later in life. Earlier accounts focused on shortness of breath, swelling in the legs, and fatigue—features doctors could see—while people living with the condition often described numbness, burning pain in the feet, or dizziness when standing, which are symptoms they felt day to day. Over time, descriptions became more precise as clinicians recognized that the same genetic change could show up differently from one person to the next.
From early theories to modern research, the story of ATTRv V122I amyloidosis has moved from scattered case reports to broader community studies. Screening in cardiology clinics, especially among Black and African American adults in the United States and people with West African roots in Europe, revealed that this variant is not rare in those populations and that many develop heart-dominant disease after midlife. At the same time, some relatives with the same variant remained well into older age, underscoring that having the variant increases risk but does not guarantee symptoms.
In recent decades, knowledge has built on a long tradition of observation. Advances in imaging, blood and urine testing, and biopsy staining allowed doctors to confirm amyloid deposits without relying on open surgery. Genetic testing then linked those deposits to the V122I variant, making diagnosis more accurate and less invasive. As medical science evolved, treatments shifted from supportive care to targeted options that stabilize or reduce amyloid formation, and clinical trials began to enroll people specifically with ATTRv V122I amyloidosis to understand outcomes over time.
Understanding the history matters for families today. Community stories often described the condition before a name existed, and that memory helps relatives recognize early symptoms of ATTRv V122I amyloidosis—such as new shortness of breath with stairs, ankle swelling, or tingling in the feet—and seek timely evaluation. Despite evolving definitions, the central lessons hold: this condition can run in families, it often shows up later in life, it may affect the heart and nerves in different ways, and today there are clearer paths to diagnosis and care than ever before.